CCFZ533X2201 - PoC Study in de Novo Renal Transplantation
Status:
Completed
Trial end date:
2017-11-29
Target enrollment:
Participant gender:
Summary
The purpose of this study was to investigate the safety, tolerability, pharmacokinetics (PK)
and potential for CFZ533 to replace calcineurin inhibitors (CNI), while providing a similar
rate of acute rejection prophylaxis and renal function in a de novo renal transplant
population receiving an allograft from standard criteria donors.